Delivery Order 36F79724D0176-36C24525N0255
Award Date
12/18/24
Potential Completion Date
12/19/24
Potential Value
$14K
Federal Agency
Veterans Integrated Service Network 5
Awardee
Janssen Biotech Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Carrollton, TX 75010, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed price delivery order contract awarded to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., by the Department of Veterans Affairs (VA). The contract has an ultimate completion date of November 22, 2024 and a ceiling value of $13,639.07. The contract is for the provision of the oncology drug BALVERSA (erdafitinib) to support healthcare services for veterans through the VA's Veterans Health Administration (VHA). Janssen Biotech is a major pharmaceutical...
This is a firm fixed price delivery order awarded by the U.S. Department of Veterans Affairs (VA) to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc. The order is valued at $18,125.50 and provides the VA's Veterans Health Administration (VHA) with the oncology medication BALVERSA (erdafitinib) to support healthcare services for veterans. The delivery order is placed against Janssen Biotech's existing $3.1 billion Federal Supply Schedule (FSS) contract for Pharmaceuticals and...
This is a firm fixed price delivery order awarded to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., by the Department of Veterans Affairs (VA) Veterans Health Administration (VHA). The order is against Janssen's Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract with a ceiling value of $17,642.95. The contract is for the chemotherapy drug BALVERSA 4 MG to support healthcare services for veterans. This delivery order is part of a larger $3.1 billion...
The Department of Veterans Affairs (VA) Veterans Health Administration (VHA) awarded a firm fixed price delivery order to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., for the chemotherapy drug BALVERSA (erdafitinib). This order was placed against Janssen's Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract, a $3.1 billion multiple award schedule that allows VHA to procure prescription drugs to support veteran healthcare programs. The $22,053.66...
The Department of Veterans Affairs (VA) awarded a firm fixed price delivery order to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., for the chemotherapy drug BALVERSA (erdafitinib). This order was issued against Janssen's Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract, a $3.1 billion multiple award schedule that allows the VA's Veterans Health Administration (VHA) to procure prescription drugs for veteran healthcare programs. The order has a...
This federal contract award to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., is for the delivery of the cancer treatment drug BALVERSA 4 MG. The award, with a ceiling value of $17,642.95, is a firm fixed price delivery order placed under a larger $3.1 billion multiple-award Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB) with the Department of Veterans Affairs (VA). The contract has an ultimate completion date of September 13, 2024 and...
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 1 awarded a $11,317.97 delivery order to Janssen Biotech, Inc. for BALVERSA medication. The contract was issued against the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), with a firm fixed price and performance period through December 31, 2021. No set-aside designation was applied. Janssen Biotech, Inc. will provide BALVERSA medication to support healthcare services for...
This is a firm fixed price delivery order awarded by the Department of Veterans Affairs Veterans Health Administration to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc. The order, valued at $62,248.81, is for the cancer treatment drug BALVERSA to support healthcare services for veterans. The delivery order was issued under Janssen's General Services Administration Multiple Award Schedule Contract for Pharmaceuticals and Drugs (FSS-61-IB), which allows the VA to efficiently...
The Department of Veterans Affairs (VA) Veterans Health Administration (VHA) awarded a firm fixed price delivery order to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., for the pharmaceutical product BALVERSA 4MG TABS. The $17,642.95 order was issued against Janssen's Pharmaceuticals and Drugs Federal Supply Schedule (FSS) contract (FSS-61-IB) and has a completion date of June 30, 2024. Janssen Biotech Inc. is a for-profit manufacturer of specialty medications, including...
This is a firm fixed price delivery order contract awarded by the Department of Veterans Affairs Veterans Health Administration to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., for the provision of the cancer treatment drug BALVERSA. The $62,165.78 contract was awarded on October 5, 2023 under Janssen's Pharmaceuticals and Drugs schedule contract (FSS-61-IB) with the General Services Administration. The delivery order, which has a completion date of March 31, 2024, will...